COVID-19 Vaccine Candidate mRNA-1273 (94.5%) beats BNT162b2 (90%) in Interim Analysis: Moderna Prepares to Submit Application for EUA with FDA

COVID-19 Vaccine Candidate mRNA-1273 (94.5%) beats BNT162b2 (90%) in Interim Analysis Moderna Prepares to Submit Application for EUA with FDA

Moderna Inc. (Nasdaq: MRNA), the developer of the messenger RNA-based vaccine candidate known as mRNA-1273, reports that the independent NIH appointed Data Safety and Monitoring Board (DSMB) for the Phase 3 clinical trial of the vaccine candidate against COVID-19 reports that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This upbeat news actually improves on the Pfizer/BioNTech interim analysis, which came in a 90% effective rate. The news involving vaccines out of the U.S. and Europe continues to stay upbeat. Moderna prepares to submit an application for an emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA).

TrialSite provides a breakdown of this important update.

What study does the data originate from?

The COVE study, which enrolled over 30,000 participants in the United States, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Re...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee